EyePoint Pharmaceuticals, Inc. is a forward-thinking biopharmaceutical company based in Watertown, Massachusetts, dedicated to the advancement of innovative therapeutics for serious ocular diseases. Utilizing its proprietary micro-insert technology, EyePoint is at the forefront of developing sustained-release drug delivery systems that effectively address substantial unmet medical needs in the ophthalmology sector. With a promising pipeline focused on the treatment of retinal diseases, the company is well-positioned for growth in critical markets including the United States, China, and the United Kingdom, reinforcing its strategic importance in the rapidly evolving eye care industry. Show more

Location: 480 PLEASANT STREET, WATERTOWN, MA, UNITED STATES, 02472, Watertown, MA, 02472, USA | Website: https://eyepoint.bio | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.119B

52 Wk Range

$3.91 - $19.11

Previous Close

$14.75

Open

$14.65

Volume

1,317,980

Day Range

$13.49 - $14.92

Enterprise Value

1.038B

Cash

74.58M

Avg Qtr Burn

-59.35M

Insider Ownership

2.77%

Institutional Own.

89.45%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
YUTIQ Details Chronic non-infectious uveitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DEXYCU Details Post-operative inflammation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DURAVYU (EYP-1901) Details Diabetic macular edema (DME)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DURAVYU™ (vorolanib intravitreal insert) (EYP-1901) Details Wet age-related macular degeneration	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EYP-1901 Details Non-proliferative diabetic retinopathy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.